A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
- Author:
Hyun YANG
1
;
Hyun Young WOO
;
Soon Kyu LEE
;
Ji Won HAN
;
Bohyun JANG
;
Hee Chul NAM
;
Hae Lim LEE
;
Sung Won LEE
;
Do Seon SONG
;
Myeong Jun SONG
;
Jung Suk OH
;
Ho Jong CHUN
;
Jeong Won JANG
;
Angelo LOZADA
;
Si Hyun BAE
;
Jong Young CHOI
;
Seung Kew YOON
Author Information
- Publication Type:Comparative Study ; Original Article
- Keywords: Carcinoma, Hepatocellular; Administration, Metronomic; Portal vein; Sorafenib; Thrombosis
- MeSH: Administration, Metronomic; alpha-Fetoproteins; Carcinoma, Hepatocellular*; Drug Therapy*; Humans; Liver*; Portal Vein; Thrombosis
- From:Clinical and Molecular Hepatology 2017;23(2):128-137
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). METHODS: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS. RESULTS: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008). CONCLUSIONS: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
